Navigation Links
Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
Date:4/14/2008

mily of secreted proteins are the first biologic agents that can be used to enhance endogenous Wnt signaling in vivo, and provide therapeutic potential in diseases that are dependent on the Wnt pathway for maintenance of tissue integrity and tissue repair. Rspo proteins are novel regulators of the Wnt pathway and were first identified by Nuvelo as potent gastrointestinal mitogens in transgenic mice(1).

About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo's development pipeline includes NU172, a direct thrombin inhibitor in Phase 1 development for use as a potential short-acting anticoagulant during medical or surgical procedures; and preclinical candidate NU206, a Wnt pathway modulator for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo is pursuing research programs in leukemia and lymphoma therapeutic antibodies and Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities.

Information about Nuvelo is available at our website at http://www.nuvelo.com or by phoning 650-517-8000.

This press release contains "forward-looking statements," which include statements regarding the timing, progress and anticipated completion of Nuvelo's clinical stage and research programs, the anticipated availability of top-line data, projected operating expenses and cash usage and the potential benefits that patients may experience from the use of our clinical stage compounds, which statements are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on our managemen
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
2. Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call
3. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
4. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
5. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , August 3, 2015 ... announced today that it has acquired ... Inc. for $300 million. With the acquisition, Shire ... drops combining 0.6% povidone iodine (PVP-I) and 0.1% ... treatment of infectious conjunctivitis, an ocular surface condition ...
(Date:8/2/2015)... 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... to discover and develop antisense therapies for cardiovascular, ... on a broad existing relationship between the two ... therapeutic areas using novel RNA-targeted treatments. It also ... antisense technology to diseases of the kidney. ...
(Date:8/2/2015)... Texas , Aug. 3, 2015  Lexicon ... that the pivotal TELESTAR Phase 3 clinical trial ... oral telotristat etiprate in treating cancer patients with ... the current standard of care. Telotristat etiprate was ... Prize-winning technology, and is the company,s first discovery ...
Breaking Medicine Technology:Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 2Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 3Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 4Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 5Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 6AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 2AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6
... 7, 2010 Where do you start when trying to ... ), an independent nonprofit that researches the best approaches to ... release of its 5th annual list of Top 10 ... free download with registration, the list features the ...
... Research Group (MRG), the global authority on medical technology ... the US clot management device market.   ... report provides important insight into the device-based treatments ... of medical device manufacturers in this field. The report ...
Cached Medicine Technology:ECRI Institute Releases 'Top 10 Health Technology Hazards for 2011' 2ECRI Institute Releases 'Top 10 Health Technology Hazards for 2011' 3Millennium Research Group to Release Their Latest US Clot Management Data 2
(Date:8/3/2015)... ... ... The U.S. Food and Drug Administration (FDA) recently approved a new non-invasive treatment ... naturally in the body and helps absorb and breakdown fat cells. Previously, plastic surgery ... are invasive procedures and very expensive for most people. Now with Kybella, there is ...
(Date:8/3/2015)... Los Angeles, CA (PRWEB) , ... August 03, 2015 , ... ... Kill Back Pain: Injection of Stem Cells Found to Release Natural Painkiller That Can ... back pain in patients. According to the report, the new study showed that harvesting ...
(Date:8/3/2015)... , ... August 03, 2015 , ... Illinois Health & ... July 31. , The acquisition includes all of IBAM NA’s cyclotron sites and ... have both, a robust regionally located business, as well as a large manufacturing hub ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... insurance brokerage firm, announced today that Joe Williams has joined its growing California ... and delivering HUB's differentiated service model to his clients. Mr. Williams will be ...
(Date:8/3/2015)... ... August 03, 2015 , ... Cambia Health ... overall performance of the company’s Medicare and Federal Employee Programs (FEP) lines of ... deliver better health for members. In this role, Scott is responsible for overseeing ...
Breaking Medicine News(10 mins):Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2
... (30), a,quadriplegic patient who is dependent on a respirator since ... LASIK procedure performed,by Drs. Jeffrey and Joseph Dello Russo. Eric ... his neck and severing his spinal cord. Since,that day, he ... his body below his upper neck down and is able ...
... Names Kaiser Permanente "Highest in,Member Satisfaction" Among All ... Kaiser Permanente Colorado is the,top-ranked commercial health plan ... a joint ranking by U.S. News & World ... To view the Multimedia News Release, go ...
... survival rates , , FRIDAY, Nov. 7 (HealthDay News) -- ... adults requiring surgery to repair a congenital heart defect, ... occurs when there,s abnormal pre-birth development of the heart ... analyzed a national database to identify 30,250 congenital heart ...
... October 31, 2008 -- Children under the age of three ... behavioral or developmental problems later compared to children who had ... at Columbia University Mailman School of Public Health and the ... children who were born into the New York State Medicaid ...
... Will Be Celebrity Host of Show at Nassau Coliseum, ... today,announced the first of its 2009 Concert Series -- a ... Cancer Research,Foundation., The show will be held on February ... go on sale Monday, November 10th at 10am,through Ticketmaster.com or ...
... National Health Science Summit, DALLAS, Nov. 7 ... today announced Dr. Valentin Fuster, director of,Mount Sinai ... Prize.,The Prize was presented to Dr. Fuster by ... Health Science Summit held on,November 7, 2008 in ...
Cached Medicine News:Health News:Historic LASIK Surgery Performed on Quadriplegic Patient to Preserve his Communication Abilities 2Health News:Audio: Kaiser Permanente is Colorado's Top Commercial and Medicare Plan on U.S. News & World Report/NCQA 'America's Best Health Plans' List 2Health News:Audio: Kaiser Permanente is Colorado's Top Commercial and Medicare Plan on U.S. News & World Report/NCQA 'America's Best Health Plans' List 3Health News:Pediatric Heart Surgeons May Be Best Choice for Adults 2Health News:General anesthesia for hernia surgery in children and risk of later developmental problems 2Health News:Barry Manilow Brings Valentine's and Music to New York With Concert to Raise Funds for Breast Cancer Research 2Health News:U.S. Preventive Medicine(R) Awards Inaugural Global Prevention Prize to Dr. Valentin Fuster of Mount Sinai Heart 2Health News:U.S. Preventive Medicine(R) Awards Inaugural Global Prevention Prize to Dr. Valentin Fuster of Mount Sinai Heart 3
A patient skin prepping solution in a self-contained applicator combining two proven broad-spectrum antimicrobials: alcohol for fast kill and fast drying (3 minutes on skin), and an iodophor for pers...
These are simple but effective single-dose, hands-off, ampulized applicators have revolutionized skin preparation in healthcare facilities....
Pre-Saturated Sponge Sticks...
... Sterile E*Kits® can be a valuable ... care; when the items necessary for a ... facility protocols and continuum of care are ... are packaged in sequence of use, allowing ...
Medicine Products: